Previous 10 | Next 10 |
Most major U.S. stock indices have rebounded sharply since hitting a multiyear low on March 23, 2020. The Dow Jones Industrial Average has gained a healthy 26% over the last two and a half weeks, while the S&P 500 has risen by nearly 23% during the same period. Despite this remarkable tu...
Shares of the mid-cap biopharma Intercept Pharmaceuticals (NASDAQ: ICPT) fell by 31.5% during the month of March, according to data from S&P Global Market Intelligence . The drugmaker's shares hit the skids last month for two reasons: Image source: Getty Images. Intercept has a r...
Raymond James has initiated coverage of NGM Biopharma (NASDAQ: NGM ) at Strong Buy, pointing to the company's lead candidate - and help from a big backer. More news on: NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Notable Calls, Healthcare stocks news, Read more ...
"Don’t panic. The time to sell is before the crash, not after." - Sir John Templeton Have you been selling during the 2020 coronavirus bear market? If you answered, "Yes," you're following conventional wisdom, which is almost always wrong. As such, your decision is driven by marke...
With the Dow Jones Industrial Average , the Nasdaq Composite Index , and the S&P 500 all down by more than 20% from their recent highs, there's no doubt that the COVID-19 pandemic has pushed U.S. stock markets into bear territory. What's more, the social distancing measures bei...
Someone's sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett Despite the threat of coronavirus, the financial market has shown signs of a rebound. In early March, you saw your stocks receded in the deep south. The drop was so severe that the bear ...
Exact Sciences (NASDAQ: EXAS ) initiated with Outperform rating and $70 (25% upside) price target at Evercore ISI. More news on: Exact Sciences Corporation, Health Catalyst, Inc., Intercept Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Citing COVID-19 disruptions, the FDA has rescheduled the advisory committee meeting on Intercept Pharmaceuticals' (NASDAQ: ICPT ) obeticholic acid in NASH to June 9 from April 22. The agency's action date on its marketing application remains, at least at this point, June 26. More news on...
NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the rescheduling of its advisor...
Whether you're a relatively new investor or have been putting your money to work for many decades, what you've witnessed over the past five weeks is unlike anything anyone has ever seen before. The spread of COVID-19 has pushed equities into bear market territory faster than any previous corr...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...